1.81
+0.02
(1.12%)
May 24 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 1.72 - 1.81 |
| 52 week | 0.04 - 6.50 |
| Open | 1.75 |
| Vol / Avg. | 2,874.00/4,625.00 |
| Mkt cap | 15.83M |
| P/E | - |
| Div/yield | - |
| EPS | -1.64 |
| Shares | 8.75M |
| Beta | 0.56 |
| Inst. own | - |
Events
May 2, 2013
Q1 2013 Nuvo Research Inc Earnings Conference Call
Mar 28, 2013
Q4 2012 Nuvo Research Inc Earnings Conference Call
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -145.27% | -55.02% |
| Operating margin | -140.60% | -53.33% |
| EBITD margin | - | -11.42% |
| Return on average assets | -49.26% | -36.99% |
| Return on average equity | -65.47% | -48.11% |
| Employees | 79 | - |
| Carbon Disclosure Rating | - | - |
Address
Unit 10, 7560 Airport Road
MISSISSAUGA, ON L4T 4H4
Canada
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)
MISSISSAUGA, ON L4T 4H4
Canada
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Nuvo Research Inc. is a specialty pharmaceutical company. The Company is engaged in building a portfolio of products for the treatment of pain through internal research and development (R&D), in-licensing and acquisition. The Company�s product portfolio includes Pennsaid, Pliaglis and Synera. Through its subsidiary Nuvo Research AG, the Company is also developing the compound WF10, for the treatment of immune related diseases. The Company�s Pain Group located in West Chester, Pennsylvania is focused on the development and commercialization of topically delivered pain products, including Pennsaid. On May 12, 2011, the Company obtained control of ZARS Pharma, Inc. On December 13, 2011, the Company acquired remaining 40% interest in Nuvo Research AG.
Officers and directors
| Daniel H. Chicoine | Chairman of the Board, Co-Chief Executive Officer | |
| John C. London | President, Co-Chief Executive Officer, Director | |
| Stephen L. Lemieux | Chief Financial Officer, Vice President | |
| Henrich R. K. Guntermann M.D. | President of Europe and Immunology Group, Director | |
| Bradley Galer | President of Pain Group | |
| Katina Loucaides | Vice President, General Counsel, Secretary | |
| David A. Copeland | Lead Independent Director | |
| Anthony E. Dobranowski | Independent Director | |
| Jacques Messier | Independent Director | |
| Theodore H. Stanley | Independent Director |